Red about the size of 3-4 quarters; Moderate itching; Vaccination site redness; tenderness; Large red rash around the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE INDURATION (Red about the size of 3-4 quarters), VACCINATION SITE PRURITUS (Moderate itching), VACCINATION SITE ERYTHEMA (Vaccination site redness), VACCINATION SITE PAIN (tenderness) and VACCINATION SITE RASH (Large red rash around the injection site) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 028L20A and 010A21A) for COVID-19 vaccination.     The patient's past medical history included Hypertension since an unknown date. Concomitant products included AMLODIPINE from 15-Jun-2013 to an unknown date for Hypertension.   On 01-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Feb-2021, the patient experienced VACCINATION SITE ERYTHEMA (Vaccination site redness) and VACCINATION SITE PAIN (tenderness). On 13-Feb-2021, the patient experienced VACCINATION SITE INDURATION (Red about the size of 3-4 quarters) and VACCINATION SITE PRURITUS (Moderate itching). In February 2021, the patient experienced VACCINATION SITE RASH (Large red rash around the injection site). In February 2021, VACCINATION SITE PRURITUS (Moderate itching), VACCINATION SITE ERYTHEMA (Vaccination site redness) and VACCINATION SITE RASH (Large red rash around the injection site) had resolved. At the time of the report, VACCINATION SITE INDURATION (Red about the size of 3-4 quarters) and VACCINATION SITE PAIN (tenderness) outcome was unknown.            Treatment included applied cold compress.     This case was linked to MOD-2021-037234 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 03-May-2021: Reporter details updated, concomitant medications added, medical history added, new events (red about the size of 3-4 quarters and Large red rash around the injection site). This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 08-Mar-2021 and was forwarded to Moderna on 09-Mar-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE INDURATION (Red about the size of 3-4 quarters), VACCINATION SITE PRURITUS (Moderate itching), VACCINATION SITE ERYTHEMA (Vaccination site redness), VACCINATION SITE PAIN (tenderness) and VACCINATION SITE RASH (Large red rash around the injection site) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 028L20A and 010A21A) for COVID-19 vaccination.     The patient's past medical history included Hypertension since an unknown date. Concomitant products included AMLODIPINE from 15-Jun-2013 to an unknown date for Hypertension.   On 01-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Feb-2021, the patient experienced VACCINATION SITE ERYTHEMA (Vaccination site redness) and VACCINATION SITE PAIN (tenderness). On 13-Feb-2021, the patient experienced VACCINATION SITE INDURATION (Red about the size of 3-4 quarters) and VACCINATION SITE PRURITUS (Moderate itching). In February 2021, the patient experienced VACCINATION SITE RASH (Large red rash around the injection site). In February 2021, VACCINATION SITE PRURITUS (Moderate itching), VACCINATION SITE ERYTHEMA (Vaccination site redness) and VACCINATION SITE RASH (Large red rash around the injection site) had resolved. At the time of the report, VACCINATION SITE INDURATION (Red about the size of 3-4 quarters) and VACCINATION SITE PAIN (tenderness) outcome was unknown.            Treatment included applied cold compress.     This case was linked to MOD-2021-037234 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 03-May-2021: Reporter details updated, concomitant medications added, medical history added, new events (red about the size of 3-4 quarters and Large red rash around the injection site).